Types
- A 2025 Lancet Commission separates clinical obesity — excess body fat that is already impairing organs or everyday activities — from preclinical obesity, excess fat with normal function but higher future risk1.
- BMI categories for adults: 25–29.9 overweight and 30 or higher obesity, with lower cutoffs often used for people of Asian descent.
- Monogenic obesity — rare, severe, early-onset obesity caused by a single gene.
Prevention
- Prevention focuses on diet quality, regular activity, enough sleep, and surroundings that make healthy choices easier.
Risk factors
- Genetics, including common variants such as FTO5
- Calorie-dense, highly processed foods and sugary drinks
- Physical inactivity and short sleep
- Some medications, including certain antipsychotics, steroids, and insulin
- Hormonal conditions such as hypothyroidism, polycystic ovary syndrome, and Cushing's syndrome
Diagnostics
- BMI alone isn't enough. Confirm excess fat with waist circumference, waist-to-hip or waist-to-height ratio, or a direct body-fat measurement such as a DEXA scan1.
- Look for effects on the body: blood pressure, blood sugar, cholesterol, liver tests, sleep apnea, and joint pain or limited mobility1.
Treatments
- Lifestyle: diet, activity, and behavior change.
- Medication: semaglutide 2.4 mg led to 14.9% average weight loss over 68 weeks, compared with 2.4% on placebo2. Tirzepatide led to up to 20.9% weight loss over 72 weeks3.
- Heart protection: in people with cardiovascular disease and overweight or obesity but no diabetes, semaglutide cut heart attacks, strokes, and cardiovascular deaths by 20%4.
- Metabolic and bariatric surgery produces the largest lasting weight loss.
- Weight tends to return when medication stops, so treatment is usually long-term.
Molecular Biomarkers
- No lab test diagnoses obesity. Labs look for its effects, including HbA1c, cholesterol, liver enzymes, and sometimes thyroid tests1.
- Hormones such as leptin are measured only in research or suspected genetic cases.
Genes
- A common variant in FTO was the first gene variant linked to body weight: people with two copies weigh about 3 kg more on average5.
- Rare single-gene causes, in genes such as MC4R, LEPR, POMC, and PCSK1, cause severe obesity in childhood; some respond to the drug setmelanotide.
Lifestyle
- Aim for 150 to 300 minutes a week of moderate activity, plus strength training to protect muscle while losing weight.
- Sleep 7 to 9 hours a night.
- Tracking food and weight and joining a support program improve results.
Nutrition
- The best diet is one you can keep up; cutting calories matters more than the exact mix of carbs and fat.
- Build meals around protein, vegetables, and fiber, and limit highly processed foods and sugary drinks.
- On GLP-1 medicines, eat enough protein and drink enough fluids.
Medical Interventions
- Metabolic and bariatric surgery: sleeve gastrectomy and gastric bypass
- Endoscopic procedures: endoscopic sleeve gastroplasty and intragastric balloons
Pharmaceutical Drugs
- Semaglutide — weekly injection; a daily pill version was approved by the FDA in December 20252,4
- Tirzepatide — weekly injection3
- Liraglutide — daily injection
- Phentermine-topiramate, naltrexone-bupropion, and orlistat
- Setmelanotide for specific genetic causes
- These medicines aren't used during pregnancy; their most common side effects are nausea and other digestive symptoms2,3.
Sources
- Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221-262. doi:10.1016/S2213-8587(24)00316-4
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
- Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889-894. doi:10.1126/science.1141634
This page summarizes published research for education. It isn't medical advice and doesn't replace care from a clinician who knows your history. Never start, stop, or change a medication without talking to your prescriber.